Become A Featured Company

Ketamine One’s KGK Science Acquisition Provides Numerous Benefits

Ryan Allway

August 19th, 2021

App, Exclusive, Psychedelics, Top News

 

KetamineOne Capital Ltd. (NEO: MEDI) (OTC: KONEF) (FFT: MYO) (“Ketamine One” or the “Company”), a North American leader in mental health treatments with a growing network of clinics, recently announced that its newly acquired and wholly-owned subsidiary, KGK Science, has over US$2.3 million in net new revenue being secured from the month of July, as its backlog of business development opportunities comes to fruition.

Acquired just a few months ago, KGK Science is a clinical research organization, or CRO, that has helped companies design and conduct over 400 clinical trials spanning 25,000 patients. The subsidiary has nearly a quarter-century worth of experience in cutting-edge industries, including nutraceuticals, cannabis, and psychedelics.

Learn more: Download Ketamine One’s investor presentation and receive updates!

The subsidiary’s prospective clients operate in the cannabis, food, non-profit, and pharmaceutical sectors and are interested in exploring topics like pharmacokinetics, cardiovascular, immunity, and serum IGF-1 concentrations. Meanwhile, its existing clients come from a wide range of industries and include both new and recurring customers.

“I am pleased with the recent increase in new business and am optimistic that the trend will continue over the near-term,” said KGK Science President and CEO Najla Guthrie in a recent press release. “KGK is positioned well to grow our business as part of Ketamine One, especially now also with access to the company’s clinic network.”

CFN Media recently spoke to Ketamine One’s Interim CEO Adam Deffett about the acquisition and why it’s so important to the company:

KGK Science has an extensive track record, blue-chip relationships, and robust cash flow. But more importantly, it enables Ketamine One to move upstream along the value chain from medical clinics to the point of designing clinical trials. The combined entity handles everything from designing clinical trials to administering treatments across 16 wholly-owned medical clinics.

“The acquisition of KGK is proving to have been well-timed and it continues to be a significant recent highlight for our company and our investors,” said Mr. Deffett in the same press release. “The combination of KGK’s industrious team with Ketamine One’s operating clinics and focus on technology is helping to accelerate our vision and goals.”

The KGK Science acquisition could also boost Ketamine One’s ambitions to acquire medical clinics. After all, many clinics are interested in a CRO-like operation that would provide them with a consistent source of revenue. At the same time, KGK Science benefits from a built-in patient population that doesn’t require outsourcing fees and eats into profitability.

Finally, the acquisition provides the management team with greater insight into the wider industry. KGK Science operates at the ground floor—when clinical trials are being designed—providing a view into what kinds of therapeutics may be coming down the pipeline and how effective they may be based on early clinical results.

Investors may want to keep an eye on the Company as its KGK Science business continues to grow. Management expects the momentum from new contracts to continue over the next 12 to 18 months. Meanwhile, the subsidiary also recently applied for a Controlled Substances Dealers License to support psychedelics-related clinical trials in Canada.

KetamineOne’s anticipated EBITDA targets by state. Source: Investor Presentation

Ketamine One aims to continue to acquire medical clinics across the United States where it can provide ketamine infusions and other therapies. Along with these clinics, the Company is developing cutting-edge technologies, such as virtual reality and wearables, to enhance and measure psychedelic experiences and improve outcomes.

To learn more, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading